CPP Applications in Immune Modulation and Disease Therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Koo, Ja-Hyun | - |
dc.contributor.author | Kim, Won-Ju | - |
dc.contributor.author | Choi, Je Min | - |
dc.date.accessioned | 2022-07-19T04:45:49Z | - |
dc.date.available | 2022-07-19T04:45:49Z | - |
dc.date.created | 2021-12-08 | - |
dc.date.issued | 2022-11 | - |
dc.identifier.issn | 1064-3745 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/169999 | - |
dc.description.abstract | About 30 years ago, the discovery of CPP improved the therapeutic approach to treat diseases and extended the range of potential targets to intracellular molecules. There are potential drug candidates for FDA approval based on active studies in basic research, preclinical, and clinical trials. Various attempts by CPP application to control the diseases such as allergy, autoimmunity, cancer, and infection demonstrated a strategy to make a new drug pipeline for successful discovery of a biologic drug for immune modulation. However, there are still no CPP-based drug candidates for immune-related diseases in the clinical stage. To control immune responses successfully, not only increasing delivery efficiency of CPPs but also selecting potential target cells and cargoes could be important issues. In particular, as it becomes possible to control intracellular targets, efforts to find various novel potential target are being attempted. In this chapter, we focused on CPP-based approaches to treat diseases through modulation of immune responses and discussed for perspectives on future direction of the research for successful application of CPP technology to immune modulation and disease therapy in clinical trial. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Humana Press Inc. | - |
dc.title | CPP Applications in Immune Modulation and Disease Therapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Je Min | - |
dc.identifier.doi | 10.1007/978-1-0716-1752-6_23 | - |
dc.identifier.scopusid | 2-s2.0-85119141038 | - |
dc.identifier.bibliographicCitation | Methods in Molecular Biology, v.2383, pp.347 - 368 | - |
dc.relation.isPartOf | Methods in Molecular Biology | - |
dc.citation.title | Methods in Molecular Biology | - |
dc.citation.volume | 2383 | - |
dc.citation.startPage | 347 | - |
dc.citation.endPage | 368 | - |
dc.type.rims | ART | - |
dc.type.docType | Book Chapter | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | cell penetrating peptide | - |
dc.subject.keywordPlus | vaccine | - |
dc.subject.keywordPlus | 6-chloro-2-(1-piperazinyl)pyrazine | - |
dc.subject.keywordPlus | cell penetrating peptide | - |
dc.subject.keywordPlus | drug | - |
dc.subject.keywordPlus | pyrazine derivative | - |
dc.subject.keywordAuthor | Allergy | - |
dc.subject.keywordAuthor | Autoimmune disease | - |
dc.subject.keywordAuthor | Cancer | - |
dc.subject.keywordAuthor | Clinical trials | - |
dc.subject.keywordAuthor | Disease therapy | - |
dc.subject.keywordAuthor | Immune cells | - |
dc.subject.keywordAuthor | Immune modulation | - |
dc.subject.keywordAuthor | Neurological disease | - |
dc.subject.keywordAuthor | Vaccine | - |
dc.identifier.url | https://link.springer.com/protocol/10.1007/978-1-0716-1752-6_23 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.